Human brain phosphodiesterase

A screening method, comprising the steps of:

• (a) contacting a polypeptide comprising the amino acid sequence of SEQ ID NO:
• 2 with at least one candidate compound in the presence of a detectable ligand known to bind said polypeptide under conditions that permit binding of said compound and said ligand with said polypeptide;
• and
• (b) determining whether said compound enhances or inhibits the binding or interaction of said ligand with said polypeptide.

A screening assay, comprising the steps of:

• (a) providing a substantially phosphodiesterase deficient host cell that exhibits a specific growth arrest phenotype associated with elevated cAMP levels;
• (b) introducing a plasmid into said host cell, said plasmid comprising a nucleic acid molecule comprising a nucleic acid sequence encoding a polypeptide comprising a polypeptide of SEQ ID NO:
• 2;
• (c) culturing said host cell under conditions sufficient to express said polypeptide and sufficient to generate a growth arrest response should said expressed polypeptide be inhibited;
• (d) contacting said host cell with at least one candidate compound;
• and
• (e) identifying at least one compound that inhibits or enhances said polypeptide, thereby discovering said growth arrest phenotype.

A screening assay, comprising the steps of:

• (a) providing a substantially phosphodiesterase deficient host cell;
• (b) introducing a polynucleotide into said host cell, said polypeptide comprising a nucleic acid sequence encoding a polypeptide comprising the polypeptide of SEQ ID NO:
• 2;
• (c) contacting said host cell with at least one candidate compound;
• and
• (d) determining whether said compound inhibits said polypeptide comprising the polypeptide of SEQ ID NO:
• 2.